{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T06:32:41Z","timestamp":1778394761902,"version":"3.51.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Natural Science Foundation of China-General Program","award":["81902678"],"award-info":[{"award-number":["81902678"]}]},{"name":"Young Elite Scientist Sponsorship Program by CAST","award":["YESS20210177"],"award-info":[{"award-number":["YESS20210177"]}]},{"name":"Shaanxi Research Fund for Young Stars of Science and Technology","award":["2022KJXX-103"],"award-info":[{"award-number":["2022KJXX-103"]}]},{"name":"Shaanxi Science Fund for Distinguished Young Scholars","award":["No. 2022JC-53"],"award-info":[{"award-number":["No. 2022JC-53"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-024-02023-9","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T10:49:29Z","timestamp":1740221369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["NK cell immunopotentiators-loaded nanoliposomes enhance ADCC effect for targeted therapy against HER2-positive breast cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Ruoxin","family":"Du","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changqing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangpeng","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengmeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gege","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huadong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"issue":"1","key":"2023_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. Ca Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"Ca Cancer J Clin"},{"issue":"4","key":"2023_CR2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","volume":"14","author":"JS Ross","year":"2009","unstructured":"Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The her-2 receptor and breast cancer: ten years of targeted anti\u2013her\u20102 therapy and personalized medicine. Oncologist. 2009;14(4):320\u201368.","journal-title":"Oncologist"},{"issue":"4785","key":"2023_CR3","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mcguire WL. Human breast cancer: correlation of relapse and survival with amplification of the her-2\/neu oncogene. Sci (American Association Advancement Science). 1987;235(4785):177\u201382.","journal-title":"Sci (American Association Advancement Science)"},{"issue":"3","key":"2023_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of her2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719\u201326.","journal-title":"J Clin Oncol"},{"issue":"6924","key":"2023_CR5","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature01392","volume":"421","author":"HS Cho","year":"2003","unstructured":"Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DJ, Leahy DJ. Structure of the extracellular region of her2 alone and in complex with the herceptin fab. Nature. 2003;421(6924):756\u201360.","journal-title":"Nature"},{"key":"2023_CR6","doi-asserted-by":"crossref","unstructured":"Maadi H, Wang Z. A novel mechanism underlying the inhibitory effects of trastuzumab on the growth of her2-positive breast cancer cells. Cells 2022;11(24).","DOI":"10.3390\/cells11244093"},{"issue":"4","key":"2023_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"RA Clynes","year":"2000","unstructured":"Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443\u20136.","journal-title":"Nat Med"},{"key":"2023_CR8","doi-asserted-by":"publisher","first-page":"1083462","DOI":"10.3389\/fimmu.2022.1083462","volume":"13","author":"F Li","year":"2022","unstructured":"Li F, Liu S. Focusing on nk cells and adcc: a promising immunotherapy approach in targeted therapy for her2-positive breast cancer. Front Immunol. 2022;13:1083462.","journal-title":"Front Immunol"},{"key":"2023_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1479-5876-6-25","volume":"6","author":"A Beano","year":"2008","unstructured":"Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, Polimeni MA, Spadi R, Donadio M, Ciuffreda L, Matera L. Correlation between Nk function and response to trastuzumab in metastatic breast cancer patients. J Transl Med. 2008;6:25.","journal-title":"J Transl Med"},{"issue":"5","key":"2023_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/ncponc0509","volume":"3","author":"R Nahta","year":"2006","unstructured":"Nahta R, Yu D, Hung M, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to her2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006;3(5):269\u201380.","journal-title":"Nat Clin Pract Oncol"},{"key":"2023_CR11","doi-asserted-by":"crossref","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J. Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses her2. N Engl J Med. 2001;344(11):783\u201392.","DOI":"10.1056\/NEJM200103153441101"},{"issue":"19","key":"2023_CR12","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1002\/cncr.33102","volume":"126","author":"S Kunte","year":"2020","unstructured":"Kunte S, Abraham J, Montero AJ. Novel her2-targeted therapies for her2-positive metastatic breast cancer. Cancer. 2020;126(19):4278\u201388.","journal-title":"Cancer"},{"issue":"13","key":"2023_CR13","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1158\/1078-0432.CCR-17-1864","volume":"24","author":"S Chumsri","year":"2018","unstructured":"Chumsri S, Sperinde J, Liu H, Gligorov J, Spano JP, Antoine M, Moreno AA, Tan W, Winslow J, Petropoulos CJ, Chenna A, Bates M, Weidler JM, Huang W, Dueck A, Perez EA. High p95her2\/her2 ratio associated with poor outcome in trastuzumab-treated her2-positive metastatic breast cancer ncctg n0337 and ncctg 98-32-52 (alliance). Clin Cancer Res. 2018;24(13):3053\u20138.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2023_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1158\/1078-0432.CCR-16-0970","volume":"23","author":"MF Mercogliano","year":"2017","unstructured":"Mercogliano MF, De Martino M, Venturutti L, Rivas MA, Proietti CJ, Inurrigarro G, Frahm I, Allemand DH, Deza EG, Ares S, Gercovich FG, Guzm\u00e1n P, Roa JC, Elizalde PV. Schillaci, Tnf\u03b1-induced mucin 4 expression elicits trastuzumab resistance in her2-positive breast cancer. Clin Cancer Res. 2017;23(3):636\u201348.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2023_CR15","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1093\/jnci\/93.24.1852","volume":"93","author":"Y Lu","year":"2001","unstructured":"Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-i receptor signaling and resistance to trastuzumab (herceptin). J Natl Cancer Inst. 2001;93(24):1852\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2023_CR16","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1158\/1078-0432.CCR-18-1131","volume":"25","author":"DR Sudhan","year":"2019","unstructured":"Sudhan DR, Schwarz LJ, Guerrero-Zotano A, Formisano L, Nixon MJ, Croessmann S, Gonz\u00e1lez EP, Sanders M, Balko JM, Avogadri-Connors F, Cutler RE, Lalani AS, Bryce R, Auerbach A, Arteaga CL. Extended adjuvant therapy with neratinib plus fulvestrant blocks er\/her2 crosstalk and maintains complete responses of er(+)\/her2(+) breast cancers: implications to the extenet trial. Clin Cancer Res. 2019;25(2):771\u201383.","journal-title":"Clin Cancer Res"},{"key":"2023_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.gene.2019.02.076","volume":"698","author":"S Noorolyai","year":"2019","unstructured":"Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B. The relation between pi3k\/akt signalling pathway and cancer. Gene. 2019;698:120\u20138.","journal-title":"Gene"},{"issue":"24","key":"2023_CR18","doi-asserted-by":"publisher","first-page":"11991","DOI":"10.1158\/0008-5472.CAN-07-2068","volume":"67","author":"S Varchetta","year":"2007","unstructured":"Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, Silva LS, Villani L, Tagliabue E, M\u00e9nard S, Costa A, Fagnoni FF. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing her2. Cancer Res. 2007;67(24):11991\u20139.","journal-title":"Cancer Res"},{"issue":"17","key":"2023_CR19","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-04-0225","volume":"10","author":"R Gennari","year":"2004","unstructured":"Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Da PG, Zambelli A, Costa A. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing her2. Clin Cancer Res. 2004;10(17):5650\u20135.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2023_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","volume":"94","author":"L Arnould","year":"2006","unstructured":"Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B. Trastuzumab-based treatment of her2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006;94(2):259\u201367.","journal-title":"Br J Cancer"},{"issue":"6","key":"2023_CR21","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1093\/annonc\/mdq585","volume":"22","author":"K Tamura","year":"2011","unstructured":"Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, Kouno T, Katsumata N, Ando M, Aogi K, Koizumi F, Nishio K, Fujiwara Y. Fc\u03b3r2a and 3a polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with her2-positive breast cancer. Ann Oncol. 2011;22(6):1302\u20137.","journal-title":"Ann Oncol"},{"key":"2023_CR22","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3389\/fimmu.2017.01544","volume":"8","author":"A Muntasell","year":"2017","unstructured":"Muntasell A, Cabo M, Servitja S, Tusquets I, Mart\u00ednez-Garc\u00eda M, Rovira A, Rojo F, Albanell J. L\u00f3pez-Botet, interplay between natural killer cells and anti-her2 antibodies: perspectives for breast cancer immunotherapy. Front Immunol. 2017;8:1544.","journal-title":"Front Immunol"},{"issue":"45","key":"2023_CR23","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1038\/onc.2008.273","volume":"27","author":"M Campoli","year":"2008","unstructured":"Campoli M, Ferrone S. Hla antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene. 2008;27(45):5869\u201385.","journal-title":"Oncogene"},{"issue":"5","key":"2023_CR24","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1158\/2326-6066.CIR-21-0170","volume":"10","author":"DN Sidiropoulos","year":"2022","unstructured":"Sidiropoulos DN, Rafie CI, Jang JK, Castanon S, Baugh AG, Gonzalez E, Christmas BJ, Narumi VH, Davis-Marcisak EF, Sharma G, Bigelow E, Vaghasia A, Gupta A, Skaist A, Considine M, Wheelan SJ, Ganesan SK, Yu M, Yegnasubramanian S, Stearns V, Connolly RM, Gaykalova DA, Kagohara LT, Jaffee EM, Fertig EJ, Roussos TE. Entinostat decreases immune suppression to promote antitumor responses in a her2\u2009+\u2009breast tumor microenvironment. Cancer Immunol Res. 2022;10(5):656\u201369.","journal-title":"Cancer Immunol Res"},{"issue":"42","key":"2023_CR25","doi-asserted-by":"publisher","first-page":"41173","DOI":"10.1074\/jbc.M302644200","volume":"278","author":"C Gross","year":"2003","unstructured":"Gross C, Koelch W, Demaio A, Arispe N, Multhoff G. Cell surface-bound heat shock protein 70 (hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme b. J Biol Chem. 2003;278(42):41173\u201381.","journal-title":"J Biol Chem"},{"issue":"4","key":"2023_CR26","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1379\/1466-1268(2001)006<0337:AMHPSN>2.0.CO;2","volume":"6","author":"G Multhoff","year":"2001","unstructured":"Multhoff G, Pfister K, Gehrmann M, Hantschel M, Gross C, Hafner M, Hiddemann W. A 14-mer hsp70 peptide stimulates natural killer (nk) cell activity. Cell Stress Chaperones. 2001;6(4):337\u201344.","journal-title":"Cell Stress Chaperones"},{"issue":"3","key":"2023_CR27","first-page":"406","volume":"24","author":"MJ Robertson","year":"1996","unstructured":"Robertson MJ, Cochran KJ, Cameron C, Le JM, Tantravahi R, Ritz J. Characterization of a cell line, nkl, derived from an aggressive human natural killer cell leukemia. Exp Hematol. 1996;24(3):406\u201315.","journal-title":"Exp Hematol"},{"issue":"2","key":"2023_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1189\/jlb.71.2.173","volume":"71","author":"MJ Robertson","year":"2002","unstructured":"Robertson MJ. Role of chemokines in the biology of natural killer cells. J Leukoc Biol. 2002;71(2):173\u201383.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"2023_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0952-7915(01)00308-9","volume":"14","author":"AD Luster","year":"2002","unstructured":"Luster AD. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol. 2002;14(1):129\u201335.","journal-title":"Curr Opin Immunol"},{"issue":"7","key":"2023_CR30","doi-asserted-by":"publisher","first-page":"e40812","DOI":"10.1371\/journal.pone.0040812","volume":"7","author":"CC Yates-Binder","year":"2012","unstructured":"Yates-Binder CC, Rodgers M, Jaynes J, Wells A, Bodnar RJ, Turner T. An ip-10 (cxcl10)-derived peptide inhibits angiogenesis. PLoS ONE. 2012;7(7):e40812.","journal-title":"PLoS ONE"},{"issue":"11","key":"2023_CR31","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s00262-009-0700-0","volume":"58","author":"TE Kute","year":"2009","unstructured":"Kute TE, Savage L, Stehle JJ, Kim-Shapiro JW, Blanks MJ, Wood J, Vaughn JP. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to adcc killing. Cancer Immunol Immunother. 2009;58(11):1887\u201396.","journal-title":"Cancer Immunol Immunother"},{"key":"2023_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/1479-5876-11-307","volume":"11","author":"B Petricevic","year":"2013","unstructured":"Petricevic B, Laengle J, Singer J, Sachet M, Fazekas J, Steger G, Bartsch R, Jensen-Jarolim E, Bergmann M. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic her2\/neu breast cancer patients. J Transl Med. 2013;11:307.","journal-title":"J Transl Med"},{"issue":"1","key":"2023_CR33","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s12967-021-03113-9","volume":"19","author":"I Schlam","year":"2021","unstructured":"Schlam I, Church SE, Hether TD, Chaldekas K, Hudson BM, White AM, Maisonet E, Harris BT, Swain SM. The tumor immune microenvironment of primary and metastatic her2- positive breast cancers utilizing gene expression and spatial proteomic profiling. J Transl Med. 2021;19(1):480.","journal-title":"J Transl Med"},{"issue":"12","key":"2023_CR34","doi-asserted-by":"publisher","first-page":"7335","DOI":"10.4049\/jimmunol.172.12.7335","volume":"172","author":"JC Lee","year":"2004","unstructured":"Lee JC, Lee KM, Kim DW, Heo DS. Elevated tgf-beta1 secretion and down-modulation of nkg2d underlies impaired nk cytotoxicity in cancer patients. J Immunol. 2004;172(12):7335\u201340.","journal-title":"J Immunol"},{"issue":"1","key":"2023_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/neuonc\/nop009","volume":"12","author":"CA Crane","year":"2010","unstructured":"Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT. Tgf-beta downregulates the activating receptor nkg2d on nk cells and cd8\u2009+\u2009t cells in glioma patients. Neuro Oncol. 2010;12(1):7\u201313.","journal-title":"Neuro Oncol"},{"issue":"1","key":"2023_CR36","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-021-00629-w","volume":"6","author":"G Zheng","year":"2021","unstructured":"Zheng G, Guo Z, Li W, Xi W, Zuo B, Zhang R, Wen W, Yang AG, Jia L. Interaction between hla-g and nk cell receptor kir2dl4 orchestrates her2-positive breast cancer resistance to trastuzumab. Signal Transduct Target Ther. 2021;6(1):236.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2023_CR37","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12943-022-01672-z","volume":"21","author":"L Tong","year":"2022","unstructured":"Tong L, Jim\u00e9nez-Cortegana C, Tay A, Wickstr\u00f6m S, Galluzzi L, Lundqvist A. Nk cells and solid tumors: therapeutic potential and persisting obstacles. Mol Cancer. 2022;21(1):206.","journal-title":"Mol Cancer"},{"issue":"11","key":"2023_CR38","doi-asserted-by":"publisher","first-page":"10935","DOI":"10.1007\/s11033-022-07865-5","volume":"49","author":"E Razeghian","year":"2022","unstructured":"Razeghian E, Kameh MC, Shafiee S, Khalafi F, Jafari F, Asghari M, Kazemi K, Ilkhani S, Shariatzadeh S, Haj-Mirzaian A. The role of the natural killer (nk) cell modulation in breast cancer incidence and progress. Mol Biol Rep. 2022;49(11):10935\u201348.","journal-title":"Mol Biol Rep"},{"key":"2023_CR39","doi-asserted-by":"crossref","unstructured":"Frutoso M, Mortier E. Nk cell hyporesponsiveness: more is not always better. Int J Mol Sci. 2019;20(18).","DOI":"10.3390\/ijms20184514"},{"issue":"4","key":"2023_CR40","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/annonc\/mdx002","volume":"28","author":"YJ Bang","year":"2017","unstructured":"Bang YJ, Giaccone G, Im SA, Oh DY, Bauer TM, Nordstrom JL, Li H, Chichili GR, Moore PA, Hong S, Stewart SJ, Baughman JE, Lechleider RJ, Burris HA. First-in-human phase 1 study of margetuximab (mgah22), an fc-modified chimeric monoclonal antibody, in patients with her2-positive advanced solid tumors. Ann Oncol. 2017;28(4):855\u201361.","journal-title":"Ann Oncol"},{"issue":"6","key":"2023_CR41","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.immuni.2020.05.001","volume":"52","author":"J Ni","year":"2020","unstructured":"Ni J, Wang X, Stojanovic A, Zhang Q, Wincher M, B\u00fchler L, Arnold A, Correia MP, Winkler M, Koch PS, Sexl V, H\u00f6fer T, Cerwenka A. Single-cell rna sequencing of tumor-infiltrating nk cells reveals that inhibition of transcription factor hif-1\u03b1 unleashes Nk cell activity. Immunity. 2020;52(6):1075\u201387.","journal-title":"Immunity"},{"issue":"6","key":"2023_CR42","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/s41418-020-00715-6","volume":"28","author":"D Li","year":"2021","unstructured":"Li D, Wang Y, Yang M, Dong Z. Mtorc1 and mtorc2 coordinate early Nk cell development by differentially inducing e4bp4 and t-bet. Cell Death Differ. 2021;28(6):1900\u20139.","journal-title":"Cell Death Differ"},{"key":"2023_CR43","doi-asserted-by":"crossref","unstructured":"Zakiryanova GK, Kustova E, Urazalieva NT, Baimuchametov ET, Nakisbekov NN, Shurin MR. Abnormal expression of c-myc oncogene in nk cells in patients with cancer. Int J Mol Sci. 2019;20(3).","DOI":"10.3390\/ijms20030756"},{"issue":"2","key":"2023_CR44","doi-asserted-by":"publisher","first-page":"972","DOI":"10.4049\/jimmunol.172.2.972","volume":"172","author":"R Gastpar","year":"2004","unstructured":"Gastpar R, Gross C, Rossbacher L, Ellwart J, Riegger J, Multhoff G. The cell surface-localized heat shock protein 70 epitope tkd induces migration and cytolytic activity selectively in human nk cells. J Immunol. 2004;172(2):972\u201380.","journal-title":"J Immunol"},{"issue":"31","key":"2023_CR45","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M. O\u2019Shaughnessy, phase iii trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794\u2013803.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2023_CR46","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O\u2019Brien","year":"2004","unstructured":"O\u2019Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C. Reduced cardiotoxicity and comparable efficacy in a phase iii trial of pegylated liposomal doxorubicin hcl (caelyx\/doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440\u20139.","journal-title":"Ann Oncol"},{"issue":"17","key":"2023_CR47","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1158\/1078-0432.CCR-20-0768","volume":"26","author":"SC Lee","year":"2020","unstructured":"Lee SC, Shimasaki N, Lim J, Wong A, Yadav K, Yong WP, Tan LK, Koh LP, Poon M, Tan SH, Ow S, Bharwani L, Yap YS, Foo M, Coustan-Smith E, Sundar R, Tan HL, Chong WQ, Kumarakulasinghe NB, Lieow J, Koe P, Goh BC, Campana D. Phase i trial of expanded, activated autologous nk-cell infusions with trastuzumab in patients with her2-positive cancers. Clin Cancer Res. 2020;26(17):4494\u2013502.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2023_CR48","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1158\/1078-0432.CCR-20-2007","volume":"27","author":"DM Collins","year":"2021","unstructured":"Collins DM, Madden SF, Gaynor N, Alsultan D, Le Gal M, Eustace AJ, Gately KA, Hughes C, Davies AM, Mahgoub T, Ballot J, Toomey S, O\u2019Connor DP, Gallagher WM, Holmes FA, Espina V, Liotta L, Hennessy BT, O\u2019Byrne KJ, Hasmann M, Bossenmaier B, O\u2019Donovan N, Crown J. Effects of her family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in her2-expressing breast cancer. Clin Cancer Res. 2021;27(3):807\u201318.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2023_CR49","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1007\/s00262-022-03146-z","volume":"71","author":"E Guti","year":"2022","unstructured":"Guti E, Regdon Z, Sturniolo I, Kiss A, Kov\u00e1cs K, Dem\u00e9ny M, Sz\u00f6\u0151r \u00c1, Vereb G, Sz\u00f6ll\u0151si J, Heged\u0171s C, Polg\u00e1r Z, Vir\u00e1g L. The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of her2 positive breast cancer cells to trastuzumab-mediated adcc. Cancer Immunol Immunother. 2022;71(9):2151\u201368.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2023_CR50","doi-asserted-by":"publisher","first-page":"255","DOI":"10.18632\/oncotarget.6353","volume":"7","author":"M Di Modica","year":"2016","unstructured":"Di Modica M, Sfondrini L, Regondi V, Varchetta S, Oliviero B, Mariani G, Bianchi GV, Generali D, Balsari A, Triulzi T, Tagliabue E. Taxanes enhance trastuzumab-mediated adcc on tumor cells through nkg2d-mediated nk cell recognition. Oncotarget. 2016;7(1):255\u201365.","journal-title":"Oncotarget"},{"key":"2023_CR51","doi-asserted-by":"publisher","first-page":"100947","DOI":"10.1016\/j.drup.2023.100947","volume":"68","author":"R Du","year":"2023","unstructured":"Du R, Zhang X, Lu X, Ma X, Guo X, Shi C, Ren X, Ma X, He Y, Gao Y, Liu Y. Pdpn positive cafs contribute to her2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent Nk cell-mediated cytotoxicity. Drug Resist Updat. 2023;68:100947.","journal-title":"Drug Resist Updat"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-024-02023-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-024-02023-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-024-02023-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T10:51:39Z","timestamp":1740221499000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-024-02023-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2023"],"URL":"https:\/\/doi.org\/10.1186\/s12964-024-02023-9","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}